Gerry Brunk

Managing Director, Lumira Capital

Brunk is a Managing Director with Lumira Capital, a North American health care venture capital firm. He joined Lumira in 2002 to establish its Boston office.  As a venture investor, Brunk has invested in and served on the boards of directors of over twenty life science companies, including Pharmasset (acquired by Gilead Sciences), MAKO Surgical (acquired by Stryker), Corvia Medical, KAI Pharmaceuticals (acquired by Amgen), Endotronix, BAROnova, Targanta Therapeutics (acquired by The Medicines Company), Cardiac Dimensions and Celtaxsys. 

Before joining Lumira Capital, Brunk was an entrepreneur who co-founded and served in a variety of management and board capacities at venture capital-funded start-ups in the pharmacy benefit management, senior living and academic technology transfer sectors. Earlier, as an Engagement Manager in the healthcare practice of The Boston Consulting Group, he advised pharmaceutical and biotechnology firms on strategic issues involving portfolio management, R&D productivity, new product launches, reimbursement and acquisitions. Brunk began his career as a member of the investment banking group of Credit Suisse First Boston where his clients included public and private healthcare companies. 

Brunk received his M.B.A. from Stanford University Graduate School of Business and a B.A. from the University of Virginia, where he studied biology and economics. He serves on the board of Southeast BIO, the oversight committee of the Wallace H. Coulter Center for Translational Research at the University of Miami, the review board of the Ivy Foundation Biomedical Innovation Fund at the University of Virginia, and as a mentor for the Canadian Technology Accelerator in Boston and the Stanford University Biodesign program.